Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 4.640
+0.030 (0.65%)
Feb 13, 2026, 4:08 PM HKT
Lepu Biopharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 700.45 | 367.79 | 225.35 | 15.57 | - | - | |
Revenue Growth (YoY) | 241.55% | 63.21% | 1347.16% | - | - | - |
Cost of Revenue | 81.19 | 74.82 | 28.28 | 2.01 | - | - |
Gross Profit | 619.27 | 292.97 | 197.08 | 13.57 | - | - |
Selling, General & Admin | 316.52 | 237.89 | 129.95 | 140.58 | 156.24 | 93.76 |
Research & Development | 423.33 | 437.7 | 458.07 | 524.29 | 791.21 | 354.43 |
Other Operating Expenses | 30.6 | 13.23 | -0.38 | -8.85 | -3.77 | -0.73 |
Operating Expenses | 770.45 | 688.82 | 587.65 | 656.02 | 943.68 | 447.45 |
Operating Income | -151.18 | -395.85 | -390.57 | -642.45 | -943.68 | -447.45 |
Interest Expense | -28.09 | -21.65 | -14.68 | -7.47 | -2.7 | -85.21 |
Interest & Investment Income | 5.52 | 4.67 | 8.18 | 8.35 | 9.1 | 10.36 |
Earnings From Equity Investments | -15.64 | -16.44 | -27.34 | -32.23 | -17.7 | -12.08 |
Currency Exchange Gain (Loss) | 5.44 | 1.33 | 0.21 | 37.75 | -2.41 | 0.04 |
Other Non Operating Income (Expenses) | -13.12 | 3.74 | 173.64 | -64 | -76.86 | -1.11 |
EBT Excluding Unusual Items | -197.06 | -424.2 | -250.56 | -700.05 | -1,034 | -535.46 |
Gain (Loss) on Sale of Investments | - | - | 220.26 | - | 5.37 | -77.99 |
Gain (Loss) on Sale of Assets | -0.87 | 0.01 | - | 0.61 | - | - |
Pretax Income | -197.93 | -424.19 | -30.3 | -699.44 | -1,029 | -613.45 |
Earnings From Continuing Operations | -197.93 | -424.19 | -30.3 | -699.44 | -1,029 | -613.45 |
Minority Interest in Earnings | 20.72 | 12.82 | 8.21 | 10.39 | 17.87 | 31.6 |
Net Income | -177.2 | -411.38 | -22.1 | -689.05 | -1,011 | -581.85 |
Net Income to Common | -177.2 | -411.38 | -22.1 | -689.05 | -1,011 | -581.85 |
Shares Outstanding (Basic) | 1,711 | 1,690 | 1,659 | 1,641 | 1,520 | 1,135 |
Shares Outstanding (Diluted) | 1,711 | 1,690 | 1,659 | 1,641 | 1,520 | 1,135 |
Shares Change (YoY) | 2.76% | 1.87% | 1.14% | 7.92% | 33.97% | 74.89% |
EPS (Basic) | -0.10 | -0.24 | -0.01 | -0.42 | -0.66 | -0.51 |
EPS (Diluted) | -0.10 | -0.24 | -0.01 | -0.42 | -0.66 | -0.51 |
Free Cash Flow | -87.42 | -229.31 | -278.84 | -591.38 | -835.12 | -661.95 |
Free Cash Flow Per Share | -0.05 | -0.14 | -0.17 | -0.36 | -0.55 | -0.58 |
Gross Margin | 88.41% | 79.66% | 87.45% | 87.12% | - | - |
Operating Margin | -21.58% | -107.63% | -173.32% | -4125.67% | - | - |
Profit Margin | -25.30% | -111.85% | -9.80% | -4424.94% | - | - |
Free Cash Flow Margin | -12.48% | -62.35% | -123.73% | -3797.71% | - | - |
EBITDA | -62.79 | -313.69 | -306.66 | -564.63 | -866.49 | -383.76 |
EBITDA Margin | -8.96% | -85.29% | -136.08% | - | - | - |
D&A For EBITDA | 88.39 | 82.16 | 83.91 | 77.82 | 77.18 | 63.69 |
EBIT | -151.18 | -395.85 | -390.57 | -642.45 | -943.68 | -447.45 |
EBIT Margin | -21.58% | -107.63% | -173.31% | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.